Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 4/20 | 0.44 |
| ▸ | LTB4R2 | Q9NPC1 | 4/20 | 0.44 |
| ▸ | PPARD | Q03181 | 8/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | LIPE | Q05469 | 1/20 | 0.40 |
| ▸ | GCGR | P47871 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6035863 | 0.92 | PPARD (0.41) | LTB4RLTB4R2PPARDPPARGLIPE | |
| SCHEMBL6035797 | 0.90 | PPARD (0.42) | LTB4RLTB4R2PPARDPPARGLIPE | |
| SCHEMBL6034987 | 0.88 | PPARD (0.40) | PPARDPPARGLIPEKDM4ELMNA | |
| SCHEMBL6036285 | 0.88 | PPARD (0.44) | LTB4RLTB4R2PPARDPPARGDHFR | |
| SCHEMBL6036252 | 0.87 | PPARG (0.42) | LTB4RLTB4R2PPARDPPARGGCGR | |
| SCHEMBL6035581 | 0.87 | PPARG (0.43) | PPARDPPARGGCGR | |
| SCHEMBL6035923 | 0.87 | SMN1; SMN2 (0.36) | LTB4RLTB4R2PPARDPPARGLIPE | |
| SCHEMBL6034614 | 0.86 | GCGR (0.39) | PPARGLIPEGCGRKDM4ELMNA | |
| SCHEMBL6035662 | 0.85 | LMNA (0.45) | PPARDPPARGGCGRLMNA | |
| SCHEMBL6036038 | 0.85 | FFAR4 (0.45) | PPARDPPARGGCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | LTB4R 1376/4885LTB4R2 1747/4885PPARD 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.